These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 33506447)
21. Total thyroidectomy (Tx) versus thionamides (antithyroid drugs) in patients with moderate-to-severe Graves' ophthalmopathy - a 1-year follow-up: study protocol for a randomized controlled trial. Brammen L; Riss P; Lukas J; Gessl A; Dunkler D; Li S; Leisser A; Rezar-Dreindl S; Eibenberger K; Selberherr A; Scheuba C; Papp A Trials; 2018 Sep; 19(1):495. PubMed ID: 30219088 [TBL] [Abstract][Full Text] [Related]
22. Medical Treatment of Graves' Orbitopathy. Salvi M; Campi I Horm Metab Res; 2015 Sep; 47(10):779-88. PubMed ID: 26361263 [TBL] [Abstract][Full Text] [Related]
23. Efficacy of selenium supplementation for mild-to-moderate Graves' ophthalmopathy in a selenium-sufficient area (SeGOSS trial): study protocol for a phase III, multicenter, open-label, randomized, controlled intervention trial. Chung CW; Jung KY; Jung EH; Lee MJ; Park YJ; Lee JK; Ahn HY; Cho SW Trials; 2023 Apr; 24(1):272. PubMed ID: 37060084 [TBL] [Abstract][Full Text] [Related]
24. Surgical treatment of globe subluxation in the active phase of the myogenic type of Graves orbitopathy: case reports. Eing F; Cruz AA Arq Bras Oftalmol; 2012; 75(2):131-3. PubMed ID: 22760806 [TBL] [Abstract][Full Text] [Related]
25. Advances in the pharmacological treatment of Graves' orbitopathy. Ruchała M; Sawicka-Gutaj N Expert Rev Clin Pharmacol; 2016 Jul; 9(7):981-9. PubMed ID: 26966785 [TBL] [Abstract][Full Text] [Related]
26. Graves' orbitopathy post-SARS-CoV-2 vaccines: report on six patients. Abeillon-du Payrat J; Grunenwald S; Gall E; Ladsous M; Raingeard I; Caron P J Endocrinol Invest; 2023 Mar; 46(3):617-627. PubMed ID: 36378488 [TBL] [Abstract][Full Text] [Related]
27. [Endocrine orbitopathy: the present view of a clinical endocrinologist]. Jiskra J Vnitr Lek; 2017; 63(10):690-696. PubMed ID: 29127744 [TBL] [Abstract][Full Text] [Related]
28. Challenges and perspectives of selenium supplementation in Graves' disease and orbitopathy. Bednarczuk T; Schomburg L Hormones (Athens); 2020 Mar; 19(1):31-39. PubMed ID: 31721133 [TBL] [Abstract][Full Text] [Related]
29. Selenium in the Treatment of Graves' Hyperthyroidism and Eye Disease. Lanzolla G; Marinò M; Marcocci C Front Endocrinol (Lausanne); 2020; 11():608428. PubMed ID: 33574798 [TBL] [Abstract][Full Text] [Related]
30. [Management of Graves' orbitopathy: evidence-based recommendations]. Ponto KA; Pitz S; Mann WJ; Weber MM; Pfeiffer N; Kahaly GJ Dtsch Med Wochenschr; 2009 Dec; 134(49):2521-4. PubMed ID: 19941237 [TBL] [Abstract][Full Text] [Related]
31. [Management of patient with Gaves' orbitopathy]. Di Fiore A; Paone L; Rendina R; D'Armiento E; Coccaro C; Alessandrini S; Marenco M; Ulisse S Clin Ter; 2012 Nov; 163(6):e463-74. PubMed ID: 23306763 [TBL] [Abstract][Full Text] [Related]
32. Current and Emerging Treatment Strategies for Graves' Orbitopathy. Genere N; Stan MN Drugs; 2019 Feb; 79(2):109-124. PubMed ID: 30659423 [TBL] [Abstract][Full Text] [Related]
33. Childhood Graves' ophthalmopathy: results of a European questionnaire study. Krassas GE; Segni M; Wiersinga WM Eur J Endocrinol; 2005 Oct; 153(4):515-21. PubMed ID: 16189172 [TBL] [Abstract][Full Text] [Related]
34. Comparative effectiveness of different treatment modalities for active, moderate-to-severe Graves' orbitopathy: a systematic review and network meta-analysis. Li H; Yang L; Song Y; Zhao X; Sun C; Zhang L; Zhao H; Pan Y Acta Ophthalmol; 2022 Sep; 100(6):e1189-e1198. PubMed ID: 34918472 [TBL] [Abstract][Full Text] [Related]
35. Teprotumumab: Interpreting the Clinical Trials in the Context of Thyroid Eye Disease Pathogenesis and Current Therapies. Winn BJ; Kersten RC Ophthalmology; 2021 Nov; 128(11):1627-1651. PubMed ID: 33930408 [TBL] [Abstract][Full Text] [Related]
36. Therapy With Different Dose Regimens of Rituximab in Patients With Active Moderate-To-Severe Graves' Orbitopathy. Campi I; Vannucchi G; Muller I; Lazzaroni E; Currò N; Dainese M; Montacchini B; Covelli D; Guastella C; Pignataro L; Fugazzola L; Arosio M; Salvi M Front Endocrinol (Lausanne); 2021; 12():790246. PubMed ID: 35145479 [TBL] [Abstract][Full Text] [Related]
37. THERAPY OF ENDOCRINE DISEASE: Endocrine dilemma: management of Graves' orbitopathy. Campi I; Vannucchi G; Salvi M Eur J Endocrinol; 2016 Sep; 175(3):R117-33. PubMed ID: 27032693 [TBL] [Abstract][Full Text] [Related]
39. PREGO (presentation of Graves' orbitopathy) study: changes in referral patterns to European Group On Graves' Orbitopathy (EUGOGO) centres over the period from 2000 to 2012. Perros P; Žarković M; Azzolini C; Ayvaz G; Baldeschi L; Bartalena L; Boschi A; Bournaud C; Brix TH; Covelli D; Ćirić S; Daumerie C; Eckstein A; Fichter N; Führer D; Hegedüs L; Kahaly GJ; Konuk O; Lareida J; Lazarus J; Leo M; Mathiopoulou L; Menconi F; Morris D; Okosieme O; Orgiazzi J; Pitz S; Salvi M; Vardanian-Vartin C; Wiersinga W; Bernard M; Clarke L; Currò N; Dayan C; Dickinson J; Knežević M; Lane C; Marcocci C; Marinò M; Möller L; Nardi M; Neoh C; Pearce S; von Arx G; Törüner FB Br J Ophthalmol; 2015 Nov; 99(11):1531-5. PubMed ID: 25953846 [TBL] [Abstract][Full Text] [Related]
40. Treatment of mild, moderate-to-severe and very severe Graves' orbitopathy. Marcocci C; Marinò M Best Pract Res Clin Endocrinol Metab; 2012 Jun; 26(3):325-37. PubMed ID: 22632369 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]